Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Increased Risk of Serious Infections During Early Anti-TNF Treatment

Will Boggs, MD  |  

“All doctors who deal with IBD therapy with TNF-alpha inhibitors will reinforce their attention in the first ninety days, especially to skin and soft tissue infections,” Dr. Chebli, who was not involved in the study, told Reuters Health by email. “Other studies need to be done to conclude if this reduction after ninety days is maintained.”

Related Articles

    Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

    NEW YORK (Reuters Health)—Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors is associated with a doubling of the risk of central nervous system demyelinating disease, researchers from Denmark report. “Based on the current evidence anti-TNF should be used cautiously in patients with an own or family history of demyelinating disease,” Dr. Nynne…

    Are We Playing It Safe?

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies

    Skin Exam Advised Before Anti-TNF-Alpha Therapy

    NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research. “Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of…